Merck Drops Nastech’s Nasal Spray
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck terminated a partnership March 1 to jointly develop Nastech's Phase I peptide YY3-36 nasal spray for treatment of obesity after concluding from a preliminary proof of concept study that it did not demonstrate efficacy